June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
Celgene highlights iberdomide data for MM at ASCO
Celgene Corp. (NASDAQ:CELG) presented data at ASCO Sunday showing that iberdomide (CC-220) plus dexamethasone led to an overall response rate (ORR) of 32%, including 17 partial responses and two very good partial responses, among 66 evaluable patients with relapsed and refractory multiple myeloma in the Phase I/II CC-220-MM-001 trial. Iberdomide is a next-generation oral immunomodulator that targets cereblon (CRBN), also a target of the biotech's Revlimid lenalidomide. Celgene has estimated that iberdomide, which is also in Phase II testing for systemic lupus erythematosus (SLE), could launch in 2021 and have incremental peak sales of more than $2 billion (see "Jump-Starting Growth").
Five Prime down on first readout for FPA150
Five Prime Therapeutics Inc. (NASDAQ:FPRX) lost $1.58 (19%) to $6.82 on Monday after reporting at ASCO over the weekend that FPA150 monotherapy led to one confirmed PR in an ovarian cancer patient among 29 patients with advanced solid tumors in the dose-escalation portion of a Phase Ia/Ib trial. Data from monotherapy expansion cohorts and early safety data from a cohort evaluating the human mAb against B7-H4 in combination with PD-1 inhibitor Keytruda pembrolizumab are expected in September...